Appendix Table 12KQ3 Total mortality—Comparative effectiveness of medical therapies with or without ACEI or ARBs for stable ischemic heart disease

Study, yearStudy DesignPopulationOutcome/DefinitionGroupEvents, n/NEvents, “X”R (95% CI)
MARCATOR, 199553RCTUndergoing elective coronary angioplastyDeathCilazapril 20mg/d
Placebo
7/1075
1/361
NR
APRES, 200054RCTUnderwent elective CABG (82%; 5–7 days prior to randomization) or PTCA (18%; 1–2 days prior to randomization) for anginaMortality due to all causesRamipril 10mg/d
Placebo
2/80
8/79
1-RR 76% (−1 to 92)
Kondo et al, 200155RCTReceived elective balloon angioplasty followed by coronary stentingTotal mortalityQuinapril 20mg/d
Control
0/49
0/50
NR
PARIS, 200156RCTUnderwent successful elective PCI with stent implantationDeathsQuinapril 40mg/d
Placebo
0/46
0/45
NR
QUIET, 200157RCTUnderwent successful elective coronary angioplasty of atherectomy within 12–72 hoursAll cause mortalityQuinapril 20mg/d
Placebo
27/878
27/872
NR
AACHEN, 200658RCTUndergoing elective coronary stent implantation (treatment started 7–14 days prior to intervention)DeathsCandesartan 32mg/d
Placebo
0/63
0/57
NR
IMAGINE, 200859RCTUnderwent CABG (7–10 days prior)Death due to any causeQuinapril 40 mg/d
Placebo
28/1280
28/1273
AHR 1.00 (0.59 to 1.69)

Outcomes provided by personal communication with corresponding author

From: Appendix C, Additional Evidence Tables and Analyses

Cover of Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease
Comparative Effectiveness of Angiotensin Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers Added to Standard Medical Therapy for Treating Stable Ischemic Heart Disease [Internet].
Comparative Effectiveness Reviews, No. 18.
Coleman CI, Baker WL, Kluger J, et al.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.